Arrowhead Pharmaceuticals Inc (ARWR) Short Interest Down 35.2% in December
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 2,919,161 shares, a decrease of 35.2% from the November 30th total of 4,507,370 shares. Approximately 4.5% of the company’s shares are short sold. Based on an average daily volume of 1,263,200 shares, the short-interest ratio is currently 2.3 days.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Allianz Asset Management GmbH purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $1,958,000. Dimensional Fund Advisors LP boosted its position in Arrowhead Pharmaceuticals by 252.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 31,765 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Arrowhead Pharmaceuticals by 10.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock valued at $742,000 after buying an additional 16,103 shares during the period. ING Groep NV purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $3,500,000. Finally, Virtu KCG Holdings LLC boosted its position in Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares during the period. 20.05% of the stock is owned by institutional investors and hedge funds.
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $3.68 on Friday. Arrowhead Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $4.54. The stock has a market cap of $275.37, a price-to-earnings ratio of -7.83 and a beta of 1.80. The company has a quick ratio of 3.63, a current ratio of 3.63 and a debt-to-equity ratio of 0.03.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.